Milestone Scientific Inc.(MLSS)Earnings, Financials & Key Ratios

MLSS•AMEX

$0.34

Price updated Jul 7, 2026

SectorHealthcare IndustryMedical Instruments Sub-IndustryDrug delivery and infusion consumables

AboutMilestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.Show more

Revenue$9M+4.0%
EBITDA-$6M+18.0%
Net Income-$6M-21.4%
EPS (Diluted)-0.07-18.4%
Gross Margin70.53%-5.4%
EBITDA Margin-61.41%+21.1%
Operating Margin-63.48%+18.9%
Net Margin-63.76%-16.7%
ROE-132.38%-94.4%

MLSS Price & Volume

Milestone Scientific Inc. (MLSS) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operating Losses Threaten Capital Runway Stability

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Liquidity and capital exhaustion

Key Thesis Takeaways

Milestone Scientific faces significant structural challenges as it struggles to scale its proprietary dental technology, evidenced by a consistent inability to convert high gross margins into positive operating income.
The company's reliance on substantial SG&A spending, which frequently exceeds $2.5 million per quarter, continues to erode shareholder equity and deplete cash reserves.
Investors should remain cautious as the narrowing liquidity buffer and history of $134.6 million in accumulated losses suggest a high probability of future dilutive financing events.

Verdict Logic

the company's inability to achieve operating leverage, combined with a rapidly depleting cash balance of $1.2 million against quarterly operating losses, presents an unsustainable risk profile for long-term investors.

MLSS Growth Metrics

Milestone Scientific Inc. (MLSS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-0.56%

5 Years10.54%

3 Years0.63%

TTM3.37%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM13.29%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM14.68%

Return on Capital

10 Years-101.84%

5 Years-79.32%

3 Years-95.77%

Last Year-117.12%

MLSS Recent Earnings

Milestone Scientific Inc. (MLSS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 2/12 qtrs (17%)●Beat Revenue 3/12 qtrs (25%)

Q2 2026Latest

May 13, 2026

Metric

Actual

Est

EPS

$0.01+33.3%

$0.01

Rev

$2M-4.0%

$2M

Q2 2026

Mar 31, 2026

Metric

Actual

Est

EPS

$0.02-33.3%

$0.01

Rev

$2M-10.6%

$2M

Q4 2025

Nov 13, 2025

Metric

Actual

Est

EPS

$0.01+33.3%

$0.01

Rev

$2M+2.2%

$2M

Q3 2025

Aug 14, 2025

Metric

Actual

Est

EPS

$0.02-100.0%

$0.01

Rev

$2M+1.0%

$2M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 13, 2026	$0.01vs $0.01+33.3%	$2Mvs $2M-4.0%
Q2 2026	Mar 31, 2026	$0.02vs $0.01-33.3%	$2Mvs $2M-10.6%
Q4 2025	Nov 13, 2025	$0.01vs $0.01+33.3%	$2Mvs $2M+2.2%
Q3 2025	Aug 14, 2025	$0.02vs $0.01-100.0%	$2Mvs $2M+1.0%

Based on last 12 quarters of dataView full earnings history →

Latest MLSS News

Recent stock market news and headlines for Milestone Scientific Inc. (MLSS)

GlobeNewsWire·Jul 1, 2026

Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY

Medical Segment Momentum Accelerates, Posting 300% Growth Versus Q2 2025 Company to Showcase Technology at American Society of Pain & Neuroscience Conference in Miami Beach, July 16–18, Alongside Board Member and ASPN Co-Founder and Vice Chairman, Dr. Dawood Sayed ROSELAND, N.J., July 01, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced preliminary, unaudited revenue for the second quarter ending June 30, 2026.

GlobeNewsWire·Jun 25, 2026

Milestone Scientific Strengthens Board to Support Next Phase of Growth

ROSELAND, N.J., June 25, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced a series of strategic governance initiatives designed to support the Company's continued evolution and long-term growth.

Peers Comparison

Key metrics vs top competitors for Milestone Scientific Inc. (MLSS)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
MLSSMilestone Scientific Inc.Current	$0.34	$29.71M	-4.82	3.99%	-63.76%	-132.38%	—
XRAYDENTSPLY SIRONA Inc.	$12.19	$2.44B	-4.06	-2.98%	-17.06%	-41.19%	—
HSICHenry Schein, Inc.	$86.84	$9.89B	26.56	4.03%	2.95%	8.14%	—
NVSTEnvista Holdings Corp	$27.13	$4.42B	96.89	8.32%	2.41%	2.18%	—
ALGNAlign Technology, Inc.	$185.22	$13.26B	32.78	0.9%	10.5%	10.7%	—
SRDXSurmodics, Inc.	$42.98	$614.51M	-52.41	-4.91%	-14.59%	-15.59%	—

Compare MLSS vs Peers

Milestone Scientific Inc. (MLSS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs XRAY

Most directly comparable listed peer for MLSS.

Scale Benchmark

vs SYK

Larger-name benchmark to compare MLSS against a more recognizable public peer.

Peer Set

Compare Top 5

vs XRAY, HSIC, NVST, ALGN

MLSS SEC Filings & Documents

Milestone Scientific Inc. (MLSS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 6, 2026·SEC

Material company update

May 6, 2026·SEC

Material company update

Apr 21, 2026·SEC

10-K Annual Reports

FY 2026

Mar 31, 2026·SEC

FY 2025

Apr 15, 2025·SEC

FY 2024

Mar 29, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 13, 2026·SEC

FY 2025

Nov 13, 2025·SEC

FY 2025

Aug 14, 2025·SEC

Get notified when MLSS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

MLSS Frequently Asked Questions

Milestone Scientific Inc. (MLSS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Milestone Scientific Inc.'s revenue?

Milestone Scientific Inc. (MLSS) reported $8.9M in revenue for fiscal year 2025. This represents a 2868% increase from $0.3M in 1996.

How fast is Milestone Scientific Inc. growing?

Milestone Scientific Inc. (MLSS) grew revenue by 4.0% over the past year. Growth has been modest.

Is MLSS profitable?

Milestone Scientific Inc. (MLSS) reported a net loss of $4.6M for fiscal year 2025.

Dividend & Returns

What is MLSS's return on equity?

Milestone Scientific Inc. (MLSS) has a return on equity (ROE) of -132.4%. Negative ROE indicates the company is unprofitable.

What is Milestone Scientific Inc.'s free cash flow?

Milestone Scientific Inc. (MLSS) had negative free cash flow of $1.8M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in MLSS back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 13, 2026

$0.01vs $0.01+33.3%

$2Mvs $2M-4.0%

Q2 2026

Mar 31, 2026

$0.02vs $0.01-33.3%

$2Mvs $2M-10.6%

Q4 2025

Nov 13, 2025

$0.01vs $0.01+33.3%

$2Mvs $2M+2.2%

Q3 2025

Aug 14, 2025

$0.02vs $0.01-100.0%

$2Mvs $2M+1.0%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

MLSSMilestone Scientific Inc.Current

$0.34

$29.71M

-4.82

3.99%

-63.76%

-132.38%

—

XRAYDENTSPLY SIRONA Inc.

$12.19

$2.44B

-4.06

-2.98%

-17.06%

-41.19%

—

HSICHenry Schein, Inc.

$86.84

$9.89B

26.56

4.03%

2.95%

8.14%

—

NVSTEnvista Holdings Corp

$27.13

$4.42B

96.89

8.32%

2.41%

2.18%

—

ALGNAlign Technology, Inc.

$185.22

$13.26B

32.78

0.9%

10.5%

10.7%

—

SRDXSurmodics, Inc.

$42.98

$614.51M

-52.41

-4.91%

-14.59%

-15.59%

—